Zymogenetics, Inc.

Baxter International Inc.

Mallinckrodt Pharma IP Trading D.a.c.

Steven D Hughes

Wayne R Kindsvogel

Wenfeng Xu

Scott R Presnell

Donald C Foster

Yasmin A Chandrasekher

Zhi Chen

Paul D Bishop

Jeffrey D Meyer

Emily N Rollins

Stacey R Dillon

Anthony W Siadak

Richard D Holly

Gerald W Lasser

Richard I Senderoff

Richard M Garcia

Margaret Dow Moore

Joyce M Lehner

Pallavur V Sivakumar

Christopher H Clegg

Pallavar V Sivakumar

Mark D Heipel

Rebecca A Johnson

Andrew J Nelson

Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.

Hemostatic microspheres

The present invention relates to blocking the activity of IL-20 polypeptide molecules. IL-20 is a cytokine that is involved in inflammatory processes and human disease. IL-20RA/IL-20RB is a common receptor for IL-20. The present invention includes anti-IL-20 antibodies and binding partners, as well as methods for antagonizing IL-20 using such antibodies and binding partners.

Anti-IL-20 antibodies and binding partners and methods of using in inflammation

The present invention relates to blocking the activity of IL-TIF polypeptide molecules. IL-TIF is a cytokine involved in inflammatory processes and human disease. The present invention includes anti-IL-TIF antibodies and binding partners, as well as methods for antagonizing IL-TIF using such antibodies and binding partners in IL-TIF-related human inflammatory diseases, amongst other uses disclosed.

Anti-IL-TIF antibodies

Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides polynucleotides, vectors, cells, and methods of production related to a new human cytokine receptor designated as 'Zcytor16.'

Human cytokine receptor

Cytokines and their receptors have proven usefulness in both basic research and as therapeutics. The present invention provides a new human cytokine receptor designated as 'Zcytor16.'

Anti-IL-TIF antibodies and methods of using in inflammation

Immunoconjugates of anti-IL-20 antibodies and hybridoma cell lines expressing anti-IL-20 antibodies

Anti-IL-TIF antibodies and methods of making

Growing community of inventors

Kenmore, WA, United States of America

Steven D Hughes